Results 151 to 160 of about 28,757,677 (326)
Molecular Oncology, EarlyView.mir‐196a promotes Esophagus Adenocarcinoma aggressiveness. On one hand, mir‐196a targets the valosin‐containing protein (VCP) mRNA, causing the accumulation of c‐MYC protein that leads to high amounts of TERT. On the other hand, mir‐196a targets the inhibitor of NFκB (NFKBIA).
Jesús García‐Castillo +8 more
wiley +1 more source
Eyespot resistance gene Pch-1 from Aegilops ventricosa is associated with a different chromosome in wheat line H-93-70 than the resistance factor in “Roazon” wheat [PDF]
, 1988 A. Delibes +4 more
openalex +1 more source
Complement factor H in AMD: Bridging genetic associations and pathobiology
Progress in retinal and eye research, 2017 C. Toomey, L. V. Johnson, C. B. Rickman
semanticscholar +1 more source
Molecular Oncology, EarlyView.The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine +10 more
wiley +1 more source
Experimental Evaluation of Conversion Factors for the [ 3 H]Thymidine Incorporation Assay of Bacterial Secondary Productivity [PDF]
, 1988 Michael Coveney, Robert G. Wetzel
openalex +1 more source
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
The endogenous heat-stable glucocorticoid receptor stabilizing factor and the H-2 locus [PDF]
, 1982 Karen L. Leach +2 more
openalex +1 more source
Structural basis for sialic acid-mediated self-recognition by complement factor H.
Nature Chemical Biology, 2015 B. Blaum +5 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source